Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis

Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $1.68 to $1.90
• 50-Day Range: $1.31 to $1.82
• 52-Week Range: $0.98 to $9.21
• Volume: 437,523 shs
• Average Volume: 307,953 shs
• Market Capitalization: $60.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.01
• Consensus Rating: Reduce

Reneo Pharmaceuticals Stock Analysis - MarketRank™

Reneo Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 570th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Reneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Reneo Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.65) to ($0.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Reneo Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Reneo Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Reneo Pharmaceuticals has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.65% of the float of Reneo Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Reneo Pharmaceuticals has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Reneo Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Reneo Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Reneo Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.65% of the float of Reneo Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Reneo Pharmaceuticals has a short interest ratio ("days to cover") of 20.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Reneo Pharmaceuticals has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.39

News Sentiment

Reneo Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Reneo Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

4 people have searched for RPHM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $355,105.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RPHM Stock Analysis - Frequently Asked Questions

How have RPHM shares performed this year?

Reneo Pharmaceuticals' stock was trading at $1.60 at the beginning of the year. Since then, RPHM shares have increased by 13.8% and is now trading at $1.82.
View the best growth stocks for 2024 here.

How were Reneo Pharmaceuticals' earnings last quarter?

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01.

When did Reneo Pharmaceuticals IPO?

Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

How do I buy shares of Reneo Pharmaceuticals?

Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/13/2024
• Today: 10/06/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RPHM
• CUSIP: N/A
• CIK: 1637715
• Web: reneopharma.com
• Phone: 858-283-0280
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.01
• High Stock Price Target: $35.55
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +505.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-77,390,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.52%
• Return on Assets: -56.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 57.86
• Quick Ratio: 57.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.66 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 33,430,000
• Free Float: 27,439,000
• Market Cap: $60.84 million
• Optionable: Optionable
• Beta: 0.21